Abbott is in a recovery phase within a longer-term downtrend: the stock is down 17.82% over the trailing year and 15.54% year-to-date, yet has rebounded 8.35% over six months and 4.18% over three months. At $104.89, the shares sit at roughly 47% of the 52-week range ($81.97 low to $132.03 high), meaning price has climbed off the lows but remains far below the highs — a positioning that reflects repair rather than momentum-driven overextension. The 39.57% maximum drawdown underscores how deep the prior decline was, and the current level suggests the market is still rebuilding conviction rather than chasing the stock. Recent momentum is clearly positive and accelerating: the stock is up 2.47% over the past month versus a 1.22% gain for SPY (relative strength of 1.25), and up 4.18% over three months versus 2.69% for SPY (relative strength of 1.49). This short-term outperformance diverges sharply from the 1-year relative strength of -33.35, a classic mean-reversion signature in which a beaten-down name begins to outperform as the longer-term downtrend decelerates. The 6-month relative strength of 0.87 shows the stock roughly tracking the market over that window, consistent with a base-building phase rather than a fresh breakdown. Key resistance sits at the 52-week high of $132.03, roughly 26% above the current price; a decisive breakout above that level would signal a full trend reversal and likely require a fundamental catalyst such as guidance stabilization or device-segment acceleration. Support rests at the 52-week low of $81.97, about 22% below current levels; a breakdown there would confirm the downtrend's resumption and likely coincide with renewed fundamental disappointment. With a beta of just 0.583, Abbott is roughly 42% less volatile than the market, which supports defensive position sizing but also means the stock will likely lag in strong risk-on rallies — a profile consistent with its low-beta healthcare defensive framing in recent coverage.

Revenue is growing at a healthy clip: Q2 2026 sales of $12.59B rose 13.02% year-over-year versus $11.14B in Q2 2025, and the sequential progression from $11.16B in Q1 2026 to $12.59B in Q2 shows solid momentum. The segment mix reveals the growth engine — Medical Devices at $5.85B (roughly 46% of quarterly revenue) is the largest contributor, followed by Diagnostics at $3.09B, Nutritional Products at $2.14B, and Established Pharmaceuticals at $1.50B. The 13% growth rate, well above Abbott's historical mid-single-digit trajectory, implies either strong underlying device/diagnostics demand or acquisition contribution (the Exact Sciences deal), and the investment case hinges on whether this pace is durable or deal-driven. Profitability is solid but uneven: Q2 2026 net income was $928M on a 7.37% net margin, down from $1.78B and a 15.97% margin in Q2 2025, while gross margin expanded to 58.0% from 56.4% a year earlier. The margin compression at the net line stems from below-the-line items — Q2 2026 interest expense of $299M (versus $121M a year ago) and a $258M net other-expense drag tied to acquisition financing — rather than operating deterioration, as operating margin held at 14.15%. Gross margin has trended up from 52.6% in Q1 2025 to 58.0% in Q2 2026, a genuine positive, but the elevated interest burden from the Exact Sciences transaction is the key swing factor for earnings recovery. The balance sheet remains conservative: debt-to-equity is just 0.289, the current ratio is 1.58, and trailing free cash flow is a robust $8.72B, with Q2 2026 FCF of $2.89B on operating cash flow of $2.49B. ROE of 12.51% and ROA of 5.33% are respectable for a capital-intensive medtech, and the company comfortably funds its $1.10B quarterly dividend and $1.05B in buybacks from internal cash generation. The main watch item is the Q1 2026 financing activity — $18.5B of debt repayment and $19.8B of acquisitions — which temporarily strained the cash position (cash fell to $6.80B from $8.52B) but left leverage at a manageable 0.29x equity.